Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | 57.8x - 63.9x | 60.9x |
| Selected Fwd P/E Multiple | 11.6x - 12.8x | 12.2x |
| Fair Value | €127.18 - €140.57 | €133.88 |
| Upside | -22.3% - -14.1% | -18.2% |
| Benchmarks | - | Full Ticker |
| Gilead Sciences, Inc. | - | NasdaqGS:GILD |
| Amgen Inc. | - | NasdaqGS:AMGN |
| Regeneron Pharmaceuticals, Inc. | - | NasdaqGS:REGN |
| Incyte Corporation | - | NasdaqGS:INCY |
| Elutia Inc. | - | NasdaqCM:ELUT |
| AbbVie Inc. | - | DB:4AB |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| GILD | AMGN | REGN | INCY | ELUT | 4AB | |||
| NasdaqGS:GILD | NasdaqGS:AMGN | NasdaqGS:REGN | NasdaqGS:INCY | NasdaqCM:ELUT | DB:4AB | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | -38.3% | -12.2% | 15.8% | -40.8% | NM- | -11.6% | ||
| 3Y CAGR | -57.4% | -11.5% | -18.2% | -67.5% | NM- | -28.2% | ||
| Latest Twelve Months | 1129.9% | 57.7% | 16.6% | -97.1% | 19.0% | -30.2% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 12.3% | 22.9% | 38.3% | 10.7% | -120.2% | 14.3% | ||
| Prior Fiscal Year | 20.9% | 23.8% | 30.1% | 16.2% | -166.7% | 8.9% | ||
| Latest Fiscal Year | 1.7% | 12.2% | 31.1% | 0.8% | -222.1% | 7.5% | ||
| Latest Twelve Months | 20.8% | 17.4% | 31.9% | 0.5% | -169.0% | 7.2% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 11.0x | 12.8x | 9.6x | 35.2x | -4.9x | 14.6x | ||
| Price / LTM Sales | 4.7x | 4.7x | 4.1x | 3.0x | 3.7x | 5.8x | ||
| LTM P/E Ratio | 22.6x | 26.8x | 12.8x | 613.2x | -2.2x | 80.5x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -2.2x | 22.6x | 613.2x | |||||
| Historical LTM P/E Ratio | 21.4x | 32.1x | 61.8x | |||||
| Selected P/E Multiple | 57.8x | 60.9x | 63.9x | |||||
| (x) LTM Net Income | 4,155 | 4,155 | 4,155 | |||||
| (=) Equity Value | 240,252 | 252,896 | 265,541 | |||||
| (/) Shares Outstanding | 1,766.4 | 1,766.4 | 1,766.4 | |||||
| Implied Value Range | 136.01 | 143.17 | 150.33 | |||||
| FX Rate: USD/EUR | 1.2 | 1.2 | 1.2 | Market Price | ||||
| Implied Value Range (Trading Cur) | 116.34 | 122.47 | 128.59 | 163.60 | ||||
| Upside / (Downside) | -28.9% | -25.1% | -21.4% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | GILD | AMGN | REGN | INCY | ELUT | 4AB | |
| Value of Common Equity | 134,693 | 159,091 | 57,644 | 13,043 | 88 | 337,834 | |
| (/) Shares Outstanding | 1,243.9 | 537.7 | 105.7 | 193.6 | 41.1 | 1,766.4 | |
| Implied Stock Price | 108.28 | 295.87 | 545.53 | 67.38 | 2.13 | 191.26 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.17 | |
| Implied Stock Price (Trading Cur) | 108.28 | 295.87 | 545.53 | 67.38 | 2.13 | 163.60 | |
| Trading Currency | USD | USD | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.17 | |